17-alpha-Estradiol

17α-estradiol is a naturally occurring, weakly estrogenic isomer of estradiol. It activates estrogen receptor alpha with much lower potency than the standard 17β form, which is why researchers describe it as "non-feminizing."

The National Institute on Aging's Interventions Testing Program (ITP), which runs the field's most rigorous mouse-longevity screen across three independent sites, found that 17α-estradiol fed at 14.4 ppm starting at 16 months of age extended median male lifespan by 19% (p<0.0001) and, when started later at 20 months, by 11% (p=0.007); 90th-percentile lifespan increased 7% (p=0.004) [1]. An earlier ITP report using a lower starting dose (10 months of age, 4.8 ppm) had already found a 12% increase in median male lifespan (p=0.0012, pooled across sites), with no effect in females in either study [1][2]. A mechanistic follow-up found that ablating the estrogen receptor alpha gene completely eliminated 17α-estradiol's metabolic benefits in male mice, and that the compound also improved metabolic parameters in male rats, extending the effect beyond one species [3].

What the evidence does not show: that these benefits are male-specific for unclear reasons, or that the effective mouse dose translates safely to humans. The mouse studies consistently find no lifespan benefit in females, and the underlying reason remains an open question. More importantly, the first published human dosing study, a pilot trial testing two doses in men, found the higher dose that produced the clearest metabolic improvements (modest reductions in body mass, adiposity, and glycosylated hemoglobin) also caused significant feminization: testicular atrophy, increased circulating estrogens, and suppressed androgens and gonadotropins [4]. This is exactly the trade-off 17α-estradiol was supposed to avoid based on the mouse data, and it appeared at doses scaled to be metabolically active in men. A separate marmoset tolerability study, done specifically because marmosets are physiologically closer to humans than mice, found two dosing regimens tolerated without gastrointestinal distress or vital sign changes, but the metabolic improvements (body mass, adiposity, HbA1c) were mild and mostly not statistically significant [5].

There is no Blueprint or self-experimentation data point for 17α-estradiol at the time of this review; it remains a research compound, not something used in any publicly documented n=1 protocol, so none is cited here.

The honest scientific critique here comes from the human pilot trial itself: the authors report their own result plainly, that the compound's central selling point (metabolic benefit without feminization) did not hold at a dose intense enough to produce metabolic benefit in men [4]. This directly narrows the gap between mouse promise and human translation that marketing around this compound tends to skip.

The honest takeaway: 17α-estradiol reliably extends male mouse lifespan in a well-controlled testing program, and the first human dosing study found the promised advantage over regular estrogen (no feminization) did not survive contact with a metabolically active human dose.